<mods xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" ID="P0b002ee18038278b">
<name type="corporate">
 <namePart>United States Government Publishing Office</namePart>
 <role>
  <roleTerm authority="marcrelator" type="text">publisher</roleTerm>
  <roleTerm authority="marcrelator" type="code">pbl</roleTerm>
</role>
 <role>
  <roleTerm authority="marcrelator" type="text">distributor</roleTerm>
  <roleTerm authority="marcrelator" type="code">dst</roleTerm>
</role>
</name>
<name type="corporate">
 <namePart>United States</namePart>
 <namePart>Government Accountability Office</namePart>
 <namePart>Health, Education, and Human Services Division</namePart>
 <role>
  <roleTerm authority="marcrelator" type="text">author</roleTerm>
  <roleTerm authority="marcrelator" type="code">aut</roleTerm>
</role>
 <description>Government Organization</description>
</name>
<typeOfResource>text</typeOfResource>
<genre authority="marcgt">government publication</genre>
<language>
 <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<extension>
 <collectionCode>GAOREPORTS</collectionCode>
 <category>Legislative Agency Publications</category>
 <waisDatabaseName>gao</waisDatabaseName>
 <branch>legislative</branch>
 <dateIngested>2010-08-12</dateIngested>
</extension>
<originInfo>
 <publisher>U.S. Government Printing Office</publisher>
 <dateIssued encoding="w3cdtf">1999-07-20</dateIssued>
 <issuance>monographic</issuance>
</originInfo>
<physicalDescription>
 <note type="source content type">deposited</note>
 <digitalOrigin>born digital</digitalOrigin>
 <extent>26 p.</extent>
</physicalDescription>
<classification authority="sudocs">GA 1.13:HEHS-99-166</classification>
<identifier type="uri">https://www.govinfo.gov/app/details/GAOREPORTS-HEHS-99-166</identifier>
<identifier type="local">P0b002ee18038278b</identifier>
<identifier type="former package identifier">f:he99166</identifier>
<recordInfo>
 <recordContentSource authority="marcorg">DGPO</recordContentSource>
 <recordCreationDate encoding="w3cdtf">2010-08-12</recordCreationDate>
 <recordChangeDate encoding="w3cdtf">2011-03-24</recordChangeDate>
 <recordIdentifier source="DGPO">GAOREPORTS-HEHS-99-166</recordIdentifier>
 <recordOrigin>machine generated</recordOrigin>
 <languageOfCataloging>
  <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</languageOfCataloging>
</recordInfo>
<accessCondition type="GPO scope determination">fdlp</accessCondition>
<extension>
 <docClass>REPORT</docClass>
 <accessId>GAOREPORTS-HEHS-99-166</accessId>
 <reportNumber>HEHS-99-166</reportNumber>
 <subject>Health care cost control</subject>
 <subject>Health care services</subject>
 <subject>Health insurance</subject>
 <subject>Comparative analysis</subject>
 <subject>Health services administration</subject>
 <subject>Beneficiaries</subject>
 <subject>Information disclosure</subject>
 <subject>Health maintenance organizations</subject>
 <subject>Drugs</subject>
 <identifier>Medicare Choice Program</identifier>
 <identifier>Medicare Program</identifier>
 <identifier>Medicare Health Maintenance Organizations Program</identifier>
 <type>Letter Report</type>
 <seriesAbbrev>HEHS</seriesAbbrev>
 <law congress="105" isPrivate="false" number="33"></law>
</extension>
<titleInfo>
 <title>Prescription Drug Benefits: Implications for Beneficiaries</title>
</titleInfo>
<abstract>Pursuant to a congressional request, GAO studied how Medicare health
maintenance organizations (HMO) manage drug formularies to control drug
expenditures and what the implications are for beneficiaries of these
formulary management activities.&lt;p/&gt;GAO noted that: (1) evaluating the prescription drug benefits Medicare
HMOs offer is an important but challenging undertaking for prospective
enrollees; (2) to determine which plan best meets their needs,
beneficiaries need to assess how HMO&apos;s use of formularies can affect
their drug benefits; (3) comparing plans can be difficult because the
types of formularies HMOs use and the way in which formularies are
managed differ considerably; (4) the choices beneficiaries make can have
a significant impact on the value of their drug benefit and
out-of-pocket costs; (5) the HMOs GAO studied varied considerably in the
types of formularies they use and the methods they use to manage them;
(6) the HMOs also use several types of formulary controls to manage drug
expenditures; (7) 12 of the 16 HMOs require the use of generic drugs
when they are available; (8) 7 of the 16 use variable copayments, with a
larger amount for brand-name drugs and a smaller amount for generics;
(9) 12 of the 16 HMOs GAO examined deleted drugs from their formularies
in four therapeutic classes that are widely used to treat health
conditions common to the elderly: hypertension, depression, ulcers, and
high cholesterol; (10) these deletions required beneficiaries to switch
to alternative formulary drugs or increase their out-of-pocket expenses,
in some cases to the full price of the drug; (11) however, 15 of the 16
also added drugs to their formularies in these classes; (12) considering
all the deletions and additions, 12 of the 16 HMOs covered as many or
more drugs in each class in January 1999 than they did in November 1997;
(13) with one exception, the HMOs continue to offer several alternatives
for physicians to prescribe in each class; (14) the HMOs also use
different methods to notify beneficiaries of formulary changes and to
consider exceptions from formulary changes; (15) while some HMOs do not
notify beneficiaries of formulary changes, others send beneficiaries a
copy of the formulary as well as a letter that informs them of specific
changes that affect them and the reasons for the changes; and (16)
although some HMOs allow a physician to except a beneficiary from a
change without providing the HMO justification for the decision, others
require that the physician document, in some cases through several
steps, that formulary alternatives are inappropriate for a beneficiary
before the HMO will agree to cover a nonformulary drug.</abstract>
<location>
 <url displayLabel="HTML rendition" access="raw object">https://www.govinfo.gov/content/pkg/GAOREPORTS-HEHS-99-166/html/GAOREPORTS-HEHS-99-166.htm</url>
 <url displayLabel="PDF rendition" access="raw object">https://www.govinfo.gov/content/pkg/GAOREPORTS-HEHS-99-166/pdf/GAOREPORTS-HEHS-99-166.pdf</url>
</location>
<identifier type="preferred citation">GAO/HEHS-99-166</identifier>
<location>
 <url displayLabel="Content Detail" access="object in context">https://www.govinfo.gov/app/details/GAOREPORTS-HEHS-99-166</url>
</location>
<note>Letter Report</note>
<extension>
 <searchTitle>GAO/HEHS-99-166; Prescription Drug Benefits: Implications for Beneficiaries;
            </searchTitle>
</extension>
<subject>
 <topic>Health care cost control</topic>
 <topic>Health care services</topic>
 <topic>Health insurance</topic>
 <topic>Comparative analysis</topic>
 <topic>Health services administration</topic>
 <topic>Beneficiaries</topic>
 <topic>Information disclosure</topic>
 <topic>Health maintenance organizations</topic>
 <topic>Drugs</topic>
 <topic>Medicare Choice Program</topic>
 <topic>Medicare Program</topic>
 <topic>Medicare Health Maintenance Organizations Program</topic>
</subject>
<relatedItem type="isReferencedBy">
 <titleInfo>
  <title>United States Public Law 33 (105th Congress)</title>
</titleInfo>
 <identifier type="public law citation">Public Law 105-33</identifier>
</relatedItem>
</mods>